# EDGAR Filing Document

**Accession Number:** 0001321834
**File Stem:** 0001493152-25-017104
**Filing Date:** 2025-10
**Character Count:** 6581
**Document Hash:** 1a0fb075ce6342434e1d23eb4060c57d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-017104.hdr.sgml**: 20251006

**ACCESSION NUMBER**: 0001493152-25-017104

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250930

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20251006

**DATE AS OF CHANGE**: 20251006

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q/C TECHNOLOGIES, INC.
- **CENTRAL INDEX KEY:** 0001321834
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36268
- **FILM NUMBER:** 251377605

**BUSINESS ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 856-848-8698

**MAIL ADDRESS:**
- **STREET 1:** 1185 AVENUE OF THE AMERICAS
- **STREET 2:** SUITE 249
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TNF Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20240725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MyMD Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20210420

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Akers Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20170413

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K/A**

**(Amendment No. 1)**

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 30, 2025**

**Q/C Technologies, Inc.**

(Exact name of Registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36268** | **22-2983783** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File No.) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| <br> **1185 Avenue of the Americas, Suite 249**<br> **New York, NY** | **10036** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(856) 848-8698**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.001 per share | QCLS | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Explanatory Note**

This Amendment No. 1 on Form 8-K/A is being filed to amend the Current Report on Form 8-K filed by Q/C Technologies, Inc. (the "Company") on October 3, 2025 (the "Original Report"), solely to include information regarding a grant of Restricted Stock Units of the Company ("RSUs") to a director of the Company that was inadvertently omitted from Item 5.02 of the Original Report. Except as described herein, no other parts of the Original Report presented incorrect information. For convenience, the Company has repeated the full text of Item 5.02 of the Original Report below with corrected information included. Capitalized terms used and not otherwise defined herein shall have the meanings given to such terms in the Original Report.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 3, 2025 (the "Grant Date"), the Board of Directors (the "Board") of the Company approved grants to each of Joshua Silverman, the Company's Executive Chairman, Christopher Schriber, a director of the Company, Bill White, a director of the Company, Stephen Friscia, a director of the Company, Mitchell Glass, the Company's Chief Medical Officer and director of the Company, Gary Rauch, the Company's Vice President of Finance, and Bruce Bernstein, a director of the Company, of an aggregate of 225,000 RSUs consisting of: (i) 8,644 RSUs to Mr. Silverman, 2,161 RSUs to Mr. Schreiber, 2,161 RUSs to Mr. White, 2,161 RUSs to Mr. Friscia, 1,080 RSUs to Mr. Glass and 1,080 RSUs to Mr. Rauch (the "Initial Grants"), which Initial Grants were issued and fully vested on the Grant Date, and (ii) 91,356 RSUs to Mr. Silverman, 22,839 RSUs to Mr. Schreiber, 22,839 RSUs to Mr. White, 22,839 RSUs to Mr. Friscia, 11,420 RSUs to Mr. Glass, 11,420 RSUs to Mr. Rauch and 25,000 RSUs to Mr. Bernstein (the "Additional Grants"), which Additional Grants will be issued, and will fully vest upon, receipt of stockholder approval of an increase in the shares reserved and available under the Company's Q/C Technologies, Inc. 2021 Equity Incentive Plan (as amended, the "Plan"). The Initial RSUs and Additional RSUs were issued or will be issued, as applicable, pursuant to the Plan.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Q/C TECHNOLOGIES, INC. | Q/C TECHNOLOGIES, INC. |
| Date: October 6, 2025 | By: | */s/ Joshua Silverman* |
|  | Name: | Joshua Silverman |
|  | Title: | Executive Chairman |

---